If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now
Key takeaways
- Moderna’s Phase 3 cancer vaccine win has revived the stock, underscoring the company’s shift from pandemic focus to broader mRNA therapeutics.
- IPO price: $23 per share
- IPO shares sold: 26.3 million
- IPO proceeds: $604.3 million
What happened
Moderna’s stock surged after a Phase 3 win for its personalized mRNA cancer vaccine (mRNA‑4157) combined with Merck’s Keytruda, lifting the share price to a record high of $497.49 on August 9 2021. The trial demonstrated that the vaccine could keep advanced melanoma from returning, marking the first Phase 3 success for an mRNA cancer therapy. The news has revived investor interest after a post‑pandemic slump.
Why it matters
The trial result signals a viable revenue stream beyond COVID‑19 vaccines, potentially restoring growth momentum for Moderna’s pipeline. It also validates the mRNA platform for personalized cancer treatments, positioning the company as a leader in a new therapeutic area. The market reaction reflects renewed…
Short-term and longer-term
Short-term. Short‑term traders should watch the stock’s volatility around the Phase 3 announcement.
Longer-term. Long‑term investors see the Phase 3 win as a pivot point for Moderna’s pipeline diversification.